Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion. Read more about Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion.
A reanalysis of cancer mortality in Canadian nuclear workers (1956-1994) based on revised exposure and cohort data. Read more about A reanalysis of cancer mortality in Canadian nuclear workers (1956-1994) based on revised exposure and cohort data.
A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Read more about A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.
A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Read more about A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer.
Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement. Read more about Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement.
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer. Read more about Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project. Read more about Segmental chromosomal alterations have prognostic impact in neuroblastoma: a report from the INRG project.
A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Read more about A phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination with carboplatin and etoposide in patients with extensive-stage small cell lung cancer.
Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma. Read more about Phase I clinical trial of the Src inhibitor dasatinib with dacarbazine in metastatic melanoma.
Oncogenic AKTivation of translation as a therapeutic target. Read more about Oncogenic AKTivation of translation as a therapeutic target.
